Advent joins the parade of new biotech funds with $235M war chest

Advent Life Sciences is joining the parade of new biotech funds debuting this year. Based in London with an investment strategy that reaches into Europe and the U.S., Advent's second dedicated life sciences fund has come up with $235 million to invest in a new roster of early- to midstage companies in the next few years. The group has invested in companies ranging from Switzerland's 4-Antibody to Menlo Park, CA-based Versartis and, like many other funds, has enjoyed a number of exits recently. The long lineup of new healthcare funds includes a $675 million wrap by Canaan recently. Late last year OrbiMed rolled out a $375 million fund and followed up a few weeks ago with a $325 million fund that will be dedicated for Asian investments. Arch Venture Partners, Venrock, Sofinnova Ventures and Versant Ventures have all raised hundreds of millions of dollars more. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.